Known targets — ChEMBL curated mechanism
DRD2DRD3HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7
The experimentally established mechanism targets of Amisulpride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | DRD1 | P21728 | 2/20 | 0.66 |
| ▸ | DRD4 | P21917 | 2/20 | 0.66 |
| ▸ | CA9 | Q16790 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amisulpride SCHEMBL29508640 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL34126 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL20206474 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29508664 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL6403721 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29506665 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL21046204 | 0.99 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL21046205 | 0.99 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL20660127 | 0.99 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29083722 | 0.98 | DRD2 (0.96) | DRD2DRD3TSHRADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119072304-A | Neuroactive steroids for the treatment of CNS related disorders | 萨奇治疗股份有限公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240050403-A1 | THERAPY OF POST-OPERATIVE EMESIS WITH AMISULPRIDE | LXO US, INC. | 2024-02-15 | — | — | US | claimed |
| US-20230263770-A1 | THERAPY OF POST-OPERATIVE NAUSEA AND VOMITING | ACACIA PHARMA LTD (GB) | 2023-08-24 | — | — | US | claimed |
| EP-4175631-A1 | THERAPY OF POST-OPERATIVE NAUSEA AND VOMITING | Acacia Pharma Ltd (GB) | 2023-05-10 | — | — | EP | claimed |
| CN-115867271-A | Therapy for postoperative nausea and vomiting | 阿卡西亚制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-20220050117-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2022-02-17 | — | — | US | claimed |
| US-20210061759-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-03-04 | — | — | US | claimed |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | claimed |
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARM INC (US) | 2015-08-20 | — | — | US | claimed |
| US-20150099741-A1 | DIAGNOSING AND TREATING PATIENTS HAVING PSYCHIATRIC DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2015-04-09 | — | — | US | claimed |
| US-20100160299-A1 | DENDRIMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-06-24 | — | — | US | claimed |
| WO-2010039861-A2 | DENDRIMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-04-08 | — | — | WO | claimed |
| EP-2134330-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | Acadia Pharmaceuticals Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | claimed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | claimed |
| WO-2008116024-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARMACEUTICALS INC. (US) | 2008-09-25 | — | — | WO | claimed |
| JP-2008528532-A | — | — | 2008-07-31 | — | — | JP | claimed |
| EP-1841417-A2 | SPM 927 FOR ADD-ON THERAPY OF SCHIZOPHRENIA | SCHWARZ PHARMA AG (DE) | 2007-10-10 | — | — | EP | claimed |
| WO-2006079547-A2 | SPM 927 FOR ADD-ON THERAPY OF SCHIZOPHRENIA | SCHWARZ PHARMA AG (DE) | 2006-08-03 | — | — | WO | claimed |
| US-6169094-B1 | ANTIPSYCHOTIC AGENTS | SANOFI-SYNTHELABO (FR) | 2001-01-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | HTR2A, HTR3A, HTR1A | DRD2 24/4885DRD3 88/4885HTR2B 7/4885 |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | HSD17B7, CYP17A1, HSD17B2 | DRD2 1735/4885DRD3 798/4885HTR2B 248/4885 |
| US-20210061759-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
| US-20100160299-A1 | DENDRIMER CONJUGATES | CD44, DDOST, ADGRE5 | DRD2 847/4885DRD3 711/4885HTR2B 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.